The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...

Euroclear plans to seize and redistribute about 3 billion euros ($3.4 billion) of Russia's funds that are frozen at the ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment.

The Food and Drug Administration accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter, the Danis ...

Young US women with breast cancer are not dying from the disease as often as a decade ago, researchers reported at the ...